Tradestie Institutional Equity Comparison Engine

ANRO vs COCP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, ANRO sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANRO N/M vs COCP N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin 0.0% vs -3063.6% ยท YoY +0.0% vs +26.9%
Momentum & Technical Winner ANRO
1Y +144.7% vs -3.0% ยท 52W Pos 64% vs 19%
Options & Structure Winner ANRO
CONSOLIDATION (8th %ile IV) vs UNCLASSIFIED (N/A IV)
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$27.77
-5.99% 1D
Market Cap $1.2B
1M Return +26.57%
1Y Return +144.67%
Forward P/E N/M
Unified AI Score
29.3 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
1M Return -2.01%
1Y Return -2.96%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANRO +144.67% COCP -2.96% Spread: +147.63 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANRO TTM Op. Margin: 0.0% COCP TTM Op. Margin: -3063.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs COCP. Trailing 12-month operating profitability (ANRO 0.0% vs COCP -3063.6%) and valuation multiples (ANRO N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANRO (4) vs COCP (3)
Institutional Metric ANRO COCP Criterion Row Winner
Market Capitalization Scale $1.2B $19.6M Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +26.9% Higher Growth COCP
Operating Margin (TTM) Profitability 0.0% -3063.6% Higher Margin ANRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -46.7% -311.7% Higher ROE ANRO
52-Week Range Position Momentum 64% ($11โ€“$37) 19% ($1โ€“$2) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 1.95ฮฒ ยท 89% Vol 1.04ฮฒ ยท 54% Vol Lower Realized Risk COCP
Unified Institutional Score Composite Signal 29.3 / 100 (SELL) 47.1 / 100 (HOLD) Higher Composite COCP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANRO vs COCP Buy Guide
ANRO CONSOLIDATION
57d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANRO nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.